IL6 and Sepsis: However, the subsequent study of sepsis patients with IL-6 concentrations >1000 pg/mL who were randomly assigned to receive afeliomab or placebo was terminated early after the primary efficacy endpoint was estimated not to be met due to interim analysis [30].